Investor Presentation: First Nine Months of 2020
61
Investor presentation
First nine months of 2020
Haemophilia is a rare disease with severe unmet medical needs
and the market is highly competitive
Number of
people (000)
Low diagnosis and treatment rates
within haemophilia
500
400
300
200
100
0
People with
haemophilia
Diagnosed
Haemophilia A Haemophilia B
Sales of recombinant haemophilia products
DKK billion
40
30
30
20
20
10
Novo NordiskⓇ
0
Inhibitor
2015 2019
2015
2019
2015
Haemophilia
with inhibitors
NovoSevenⓇ
Coagil VII
Obizur¹
Haemophilia A
NovoEight®
2019
Haemophilia B
RefixiaⓇ/RebinynⓇ
Advate/Adynovate
Idelvion
Kogenate/Kovaltry/Jivi
Rixubis
Feiba²
Hemlibra³
Xyntha/Refacto
Alprolix
Eloctate/Elocta
Benefix
Helixate/Afstyla
Hemlibra
Note: The inhibitor segment includes acquired haemophilia patients, patients with low titre inhibitors or with transient inhibitors,
and patients on immune tolerance induction.
Source: World Federation of Haemophilia (WFH) - Annual survey 2018; WFH: Closing the gap - achieving optimal care, Haemophilia
2012.
1 Obizur only indicated for acquired haemophilia; 2 Plasma-derived; 3 Part of the Hemlibra sales is used for treatment of haemophilia
A patients in 2019
Source: Company reported sales and EvaluateView entire presentation